DV
Dividend Vision

ABUS — Arbutus Biopharma Corp

Arbutus Biopharma Corp (ABUS)

Total return is -33.7% over the past 15.7 years, 788.2 points behind SPY at 754.5%. Its deepest 1-year drawdown was 25.9%.

ABUS is a single-stock equity holding in Arbutus Biopharma Corp, a biopharmaceutical company, rather than a diversified ETF. The holding does not currently pay distributions, resulting in a N/A distribution rate, and detailed fund characteristics including expense ratio and assets under management are not available. This instrument appeals primarily to investors seeking concentrated exposure to a specific biotech company rather than those pursuing dividend income or broad portfolio diversification.

ABUS key facts

Asset type
Stock
Asset class
Equity
Inception date
11/15/2010
Last close
$4.67
Market cap
$900,771,968
Average volume
1438732.0
Beta
0.618
Payout ratio
0.0
P/E ratio
5.494
Forward P/E
10.2459
EPS
$0.83